Omnicell (NASDAQ:OMCL) Updates Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share guidance of $0.55-$0.62 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on OMCL. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 19th. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday. Benchmark reissued a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, Wells Fargo & Company raised their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $49.14.

Omnicell Price Performance

Shares of OMCL stock traded up $0.03 on Friday, reaching $48.67. The company’s stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. The company has a market capitalization of $2.24 billion, a P/E ratio of -124.79, a PEG ratio of 58.48 and a beta of 0.83. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The stock’s 50 day simple moving average is $43.34 and its 200-day simple moving average is $35.32. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The firm had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter last year, the firm posted $0.29 EPS. The company’s revenue was down 7.4% compared to the same quarter last year. As a group, equities analysts predict that Omnicell will post 0.64 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.